CD8+ T cells play a central role in eradicating intracellular pathogens, but also are important for noninfectious diseases, including cancer and autoimmunity. The ability to clinically manipulate CD8+ T cells to target cancer and autoimmune disease is limited by our ignorance of relevant self-peptide target antigens. In this issue of the
Devin Dersh, Jonathan W. Yewdell
Summary of experimental approach and salient conclusions.
As reported in this issue, Pearson et al. isolated B cells from 18 individuals, expressing a total of 27 MHC class I allomorphs, and identified surface-presented peptides using mild acid elution coupled with mass spectrometry. Simultaneously, personalized genetic databases were created using transcriptome and exome sequencing from each donor. Together, the peptide identification and sequencing information allowed for the mapping of MAPs at their source locations within the genome.